Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advan-ced breast cancer: NeoTRIP Michelangelo randomized study.

Gianni, L; Huang, CS; Egle, D; Bermejo, B; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Bianchini, G; Russo, S; Ciruelos, EM; Greil, R; Semiglazov, V; Colleoni, M; Kelly, C; Mariani, G; Del Mastro, L; Maffeis, I; Valagussa, P; Viale, G.
Ann Oncol. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. E-pub 2022 Feb 17.
https://pubmed.ncbi.nlm.nih.gov/35182721/